While the protective effect of pharmacological intervention with long-acting FGF21 on human liver steatosis has been uncovered (Sanyal et al., 2019; Harrison et al., 2021; Aggarwal et al., 2022), mechanisms underlying attenuated steatosis as well all the anti-inflammatory and anti-fibrotic effects of FGF21 on NASH are still largely unexplored. This evidence concerns the gene FGF21 and steatosis.